UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

From Critical Race Theory to the January 6th Insurrection Speech: The High School Classroom and the Politics of Division

Cultural studies, critical methodologies, 2022-10, Vol.22 (5), p.505-512

Walker, Katrina M.

2022

Volltextzugriff (PDF)

Embedding an enriched environment in an acute stroke unit increases activity in people with stroke: a controlled before–after pilot study

Clinical rehabilitation, 2017-11, Vol.31 (11), p.1516-1528

2017

Volltextzugriff (PDF)

MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

BMJ open, 2021-03, Vol.11 (3), p.e046225-e046225

2021

Volltextzugriff (PDF)

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

Blood cancer journal (New York), 2022-04, Vol.12 (4), p.52-52, Article 52

2022

Volltextzugriff (PDF)

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

Trials, 2020-10, Vol.21 (1), p.826-826, Article 826

2020

Volltextzugriff (PDF)

Endogenous γ-Hydroxybutyric Acid Concentrations in Saliva Determined by Gas Chromatography-Mass Spectrometry

Journal of analytical toxicology, 2011-04, Vol.35 (3), p.148-152

2011

Volltextzugriff (PDF)

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Clinical and translational radiation oncology, 2020-11, Vol.25, p.61-66

2020

Volltextzugriff (PDF)

Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs

Programme grants for applied research, 2022-02, Vol.10 (1), p.1-110

2022

Volltextzugriff (PDF)

The effect of an enriched environment on activity levels in people with stroke in an acute stroke unit: protocol for a before-after pilot study

Pilot and feasibility studies, 2016-08, Vol.2 (1), p.36-36, Article 36

2016

Volltextzugriff (PDF)

Spirituality and Academic Performance among African American College Students

Journal of black psychology, 2002-05, Vol.28 (2), p.107-121

2002

Volltextzugriff (PDF)

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Journal of clinical oncology, 2023-08, Vol.41 (23), p.3945-3955

2023

Volltextzugriff (PDF)

The Role of Ethnocultural Variables in Response to Terrorism

Cultural diversity & ethnic minority psychology, 2003-08, Vol.9 (3), p.251-262

2003

Volltextzugriff (PDF)

Early phase clinical trials extension to guidelines for the content of statistical analysis plans

BMJ (Online), 2022-02, Vol.376, p.e068177

2022

Volltextzugriff (PDF)

Online Symptom Monitoring During Pelvic Radiation Therapy: Randomized Pilot Trial of the eRAPID Intervention

International journal of radiation oncology, biology, physics, 2023-03, Vol.115 (3), p.664-676

2023

Volltextzugriff (PDF)

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8001-8001

2021

Volltextzugriff (PDF)

MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

BMJ open, 2021-03, Vol.11 (3), p.e046225

2021

Volltextzugriff (PDF)

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.4327-4327

2019

Volltextzugriff (PDF)

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

Blood, 2018-11, Vol.132 (Supplement 1), p.4482-4482

2018

Volltextzugriff (PDF)

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

Blood, 2018-11, Vol.132 (Supplement 1), p.3274-3274

2018

Volltextzugriff (PDF)

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Blood, 2019-11, Vol.134 (Supplement_1), p.3162-3162

2019

Volltextzugriff (PDF)

OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S8-S8

2021

Volltextzugriff (PDF)

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the ‘Myeloma UK Seven’ Biomarker Trial

Blood, 2017-12, Vol.130, p.1851-1851

2017

Volltextzugriff (PDF)

Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE

JCO precision oncology, 2022-11, Vol.6 (6), p.e2200133

2022

Volltextzugriff (PDF)

The Professional Preparation of African American Graduate Students: A Student Perspective

Professional psychology, research and practice, 2001-12, Vol.32 (6), p.581-584

2001

Volltextzugriff (PDF)

1 – 25 von 249

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(224)
Mit Volltextzugriff
(214)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(244)
Portugiesisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(139)
Life Sciences & Biomedicine
(121)
Humans
(108)
Female
(68)
Male
(68)
Adolescent
(30)
Adult
(30)
Child
(26)
Social Sciences
(24)
Middle Aged
(23)
Aged
(21)
Covid-19
(21)
Animals
(18)
Neurosciences & Neurology
(18)
Psychiatry
(17)
Multidisciplinary Sciences
(16)
Neurosciences
(16)
Science & Technology - Other Topics
(16)
Biological And Medical Sciences
(15)
General & Internal Medicine
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Biological Psychiatry
(7)
Blood
(6)
Australasian Journal Of Early Childhood
(5)
Journal Of Clinical Oncology
(5)
Nature Communications
(5)
The Lancet
(5)
Bmj Open
(4)
Clinical Infectious Diseases
(4)
Nature
(4)
Neuroimage
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

From Critical Race Theory to the January 6th Insurrection Speech: The High School Classroom and the Politics of Division

Embedding an enriched environment in an acute stroke unit increases activity in people with stroke: a controlled before–after pilot study

MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

Endogenous γ-Hydroxybutyric Acid Concentrations in Saliva Determined by Gas Chromatography-Mass Spectrometry

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs

The effect of an enriched environment on activity levels in people with stroke in an acute stroke unit: protocol for a before-after pilot study

Spirituality and Academic Performance among African American College Students

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

The Role of Ethnocultural Variables in Response to Terrorism

Early phase clinical trials extension to guidelines for the content of statistical analysis plans

Online Symptom Monitoring During Pelvic Radiation Therapy: Randomized Pilot Trial of the eRAPID Intervention

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial

MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the ‘Myeloma UK Seven’ Biomarker Trial

Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE

The Professional Preparation of African American Graduate Students: A Student Perspective

Suchergebnisse filtern